Literature DB >> 19329327

Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Xian-Chao Cheng1, Xin-Yong Liu, Wen-Fang Xu, Xiu-Li Guo, Ning Zhang, Yu-Ning Song.   

Abstract

A series of novel acylpiperazinyl Ligustrazine derivatives was designed, synthesized, and their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities were evaluated. The results showed that compound E33 displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound E1 was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329327     DOI: 10.1016/j.bmc.2009.03.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.

Authors:  Joseph Ramli; Pedro CalderonArtero; Robert C Block; Shaker A Mousa
Journal:  Cardiol J       Date:  2011       Impact factor: 2.737

2.  Ligustrazinyl amides: a novel class of ligustrazine-phenolic acid derivatives with neuroprotective effects.

Authors:  Guoliang Li; Xin Xu; Kuo Xu; Fuhao Chu; Jixiang Song; Shen Zhou; Bing Xu; Yan Gong; Huazheng Zhang; Yuzhong Zhang; Penglong Wang; Haimin Lei
Journal:  Chem Cent J       Date:  2015-03-04       Impact factor: 4.215

3.  Antithrombotic effect of ligustrazine hydrochloride injection on the model of induced arteriovenous shunt thrombosis.

Authors:  Peng Wang; Chun-Hua Luo; Qun-Xing Wang; Qian-Yuan Li; Peng Li; Xiao-Hui Yuan
Journal:  J Res Med Sci       Date:  2013-08       Impact factor: 1.852

4.  Novel Homo-Bivalent and Polyvalent Compounds Based on Ligustrazine and Heterocyclic Ring as Anticancer Agents.

Authors:  Jiawen Wang; Ge Hong; Guoliang Li; Wenzhi Wang; Tianjun Liu
Journal:  Molecules       Date:  2019-12-09       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.